Cases & Deals

Takeda expands patent portfolio relating to anticancer drugs and clinical stage anticancer drug candidates

Clients Takeda Pharmaceuticals U.S.A., Inc.

Jones Day represents Takeda Pharmaceuticals U.S.A., Inc. in worldwide patent prosecution and portfolio development for approved and clinical stage anticancer drugs and drug candidates, including ALUNBRIGTM (brigatinib), which is indicated for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.